Intangible Assets

RNXT appears to have limited evidence of proprietary IP or regulatory exclusivity in the provided metrics, so its pricing power is not visibly protected versus peers.

Negative ROIC and ROCE indicate that any intangible advantage is not yet translating into durable economic returns, unlike stronger peers with proven monetization.

The absence of disclosed 5-year margin or growth history in the supplied data makes it difficult to support a durable brand or clinical differentiation moat versus established medtech peers.

In a competitive healthcare technology/medtech setting, weaker returns suggest customers likely have credible alternatives, which reduces the durability of any intangible asset advantage.

Switching Costs

The provided data do not show evidence of embedded workflows, long-term contracts, or integration depth that would make RNXT costly to replace versus peers.

Negative profitability suggests customers are not yet locked in by a high-cost switching structure that preserves margins over time.

Compared with larger peers that often benefit from installed-base service relationships and validated clinical adoption, RNXT does not show clear retention advantages in the supplied metrics.

A very negative cash conversion cycle can reflect working-capital intensity rather than customer lock-in, so it does not by itself demonstrate durable switching costs.

Network Effects

The supplied information does not indicate a user, data, or ecosystem flywheel that would make RNXT more valuable as adoption rises.

Unlike platform-based peers with compounding network effects, RNXT’s metrics do not show evidence that customer growth is reinforcing product value or retention.

Negative ROIC and weak asset efficiency are inconsistent with a network-driven moat that would typically support superior monetization versus peers.

No peer-dependent ecosystem control is evident in the provided data, so network effects appear minimal or absent.

Cost Advantage

RNXT’s negative ROIC and ROCE suggest it is not currently converting operations into a cost advantage versus peers.

Asset turnover is low, which implies the asset base is not being used more efficiently than competitors to support structurally lower unit costs.

The very negative cash conversion cycle may help working capital in the short term, but it does not establish a persistent cost edge unless it is paired with superior margins and scale.

Relative to stronger peers that can spread fixed costs across larger volumes, RNXT does not show evidence of a durable procurement, manufacturing, or operating-cost advantage in the supplied data.

Efficient Scale

The available metrics do not show that RNXT operates in a niche where market size is small enough to support efficient-scale protection against entrants.

Negative returns indicate the company has not yet demonstrated that scale is creating a defensible cost or margin structure versus peers.

Compared with established competitors that can dominate specialized channels or installed bases, RNXT does not show evidence of industry capacity discipline or scale-based barriers.

Without evidence of concentrated market share or regulated scarcity, efficient scale appears weak and unlikely to protect pricing power over 5–10 years.

Overall Score

RNXT’s moat appears weak versus peers because the supplied metrics show negative capital returns, low asset efficiency, and no clear evidence of proprietary IP, switching costs, network effects, cost advantage, or efficient-scale protection.